Mounjaro and Zepbound, explained

Tirzepatide can help reduce hunger, body weight and blood sugar. The first month is about starting treatment and assessing tolerability—not matching the weight loss measured after many months in a trial.

The brand and treatment goal shape the dose plan. A higher amount is not automatically the right target, and nausea is not proof of a better response.

The first month Weight-loss results

Tirzepatide

Weekly under-skin injection

Zepbound

Weight management

2.5 mg weekly for four weeks, then 5 mg.

Maintenance choices
5, 10 or 15 mg weekly

Mounjaro

Type 2 diabetes

Starts at 2.5 mg weekly. Later increases depend on blood-sugar needs.

Adult maximum
15 mg weekly
US adult label context. Later increases use 2.5 mg steps after at least four weeks at the current dose. Zepbound's sleep-apnea maintenance differs; see below. Zepbound · Mounjaro

What tirzepatide is

Tirzepatide is the medicine in Mounjaro and Zepbound. In the US, Mounjaro treats type 2 diabetes; Zepbound is the weight-management brand and also treats moderate-to-severe obstructive sleep apnea in adults with obesity. Both are weekly injections under the skin. Their product instructions and approved uses differ. Mounjaro label, Zepbound label.

Tirzepatide acts on two hormone pathways, GIP and GLP-1, that affect food intake and blood-sugar regulation. The practical aim is a useful weight or glucose response with acceptable tolerability. Complete appetite suppression and strong nausea are not treatment targets.

Dose, how often and how long

Weekly

A continuing routine

Both injections are used once weekly, on the same day, with or without meals.

At least 4 weeks

Between later increases

Increases are in 2.5 mg steps. Treatment goals and tolerability still matter.

Ongoing

No fixed short course

Dose escalation and treatment duration are different questions.

The opening map and details below describe US adult injection labels. They are not a switching conversion.

Zepbound for weight management

Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg. After gradual increases, its weight-management maintenance choices are 5, 10 or 15 mg weekly. The maximum is 15 mg.

Further increases are in 2.5 mg steps after at least four weeks at the current dose, considering response and tolerability. 2.5 mg is introductory, not a maintenance dose. For moderate-to-severe obstructive sleep apnea in adults with obesity, the labeled maintenance doses are 10 or 15 mg. Zepbound sections 1–2.

Mounjaro for type 2 diabetes

Mounjaro starts at 2.5 mg weekly. Its current label makes later increases conditional on additional blood-sugar control, with an adult maximum of 15 mg weekly.

Mounjaro’s current US instructions do not require everyone to move to 5 mg at week five. The next step depends on blood-sugar needs. Do not copy Zepbound’s introductory-dose rule into a different brand’s instructions. Current Mounjaro dosing.

What to expect in the first month

Appetite, weight and blood sugar are different ways of assessing response. For diabetes, glucose readings and the planned follow-up matter even if the scale changes little. For weight management, a first month at the introductory Zepbound dose cannot be compared fairly with a 72-week result after escalation.

You do not need nausea to demonstrate that the medicine is doing something. Conversely, persistent digestive symptoms deserve attention even if weight is falling. Record what you notice—appetite, weight trend, symptoms and blood sugar when relevant—so the prescribing review has more to work with than whether an injection felt “strong.”

Why weekly doses overlap

Tirzepatide stays in the body between injections. Zepbound’s label gives a half-life of about five to six days and describes a repeating blood-level pattern after roughly four weeks of consistent weekly dosing. A hungrier day is not a measurement showing the medicine has disappeared. Label timing.

The plotter helps show overlap between doses. It does not predict how hungry, nauseated or energetic a particular person will feel.

Trial results

The large weight-loss results were measured over many months. This direct comparison gives a more useful reference than comparing unrelated before-and-after stories:

SURMOUNT-5: average body-weight reduction at 72 weeks

Tirzepatide
20.2 %
Semaglutide
13.7 %
751 adults with obesity without diabetes; randomized open-label trial. Highest tolerated weekly doses: tirzepatide 10/15 mg or semaglutide 1.7/2.4 mg. Group averages include the study's handling of people who stopped treatment. Aronne et al., NEJM 2025

These are group averages at the specified doses. The newer 7.2 mg Wegovy injection and semaglutide tablets were outside this trial. For the fuller brand and side-effect comparison, see semaglutide versus tirzepatide.

Side effects

Nausea, diarrhea, constipation and vomiting are common, often during dose increases. Persistent severe abdominal pain, repeated vomiting or inability to keep fluids down needs medical assessment. People also using insulin or sulfonylureas need a plan for the increased risk of low blood sugar. Product precautions.

Two practical points can be easy to miss:

  • The contraceptive pill: tirzepatide can reduce its effectiveness. The labels advise a non-oral method or added barrier protection for four weeks after starting and after each dose increase.
  • Other medicines and procedures: slowed stomach emptying can affect oral medicines and matters before anesthesia. Tell the treating team about tirzepatide and the exact product used.

A personal or family history of medullary thyroid carcinoma, or MEN 2, is a labeled contraindication. The product leaflet contains the full precautions; a reputation for fewer side effects than another drug does not replace them. Mounjaro, Zepbound.

How it compares

Tirzepatide produced greater average weight loss in the direct trial above, but that does not make switching an automatic next step. There is no semaglutide-to-tirzepatide dose-conversion table in the product labels, and the labels do not recommend combining the treatments. A switch needs a plan for the current medicine, treatment goal and tolerability.

Digestive symptoms can occur with either drug. Discuss which symptoms are limiting treatment rather than assuming a larger milligram number or two hormone targets will solve the problem. The comparison guide includes side-effect rates measured in the same trial.

Planning beyond the starting month

A four-week escalation interval is not a four-week treatment course. In SURMOUNT-4, people switched to placebo after initial tirzepatide treatment regained weight, while those continuing treatment lost more. That makes a maintenance and follow-up plan useful before stopping at a goal weight. Original withdrawal study.

Frequently asked questions

Does tirzepatide cause muscle loss?

Weight reduction can include both fat and lean tissue. In a 160-person SURMOUNT-1 substudy, DXA scans found reductions in both. DXA lean mass is not a direct measurement of skeletal muscle alone, and a drug-level curve cannot predict a person’s body-composition change.

Does a five-day half-life mean dosing every five days?

No. Half-life describes the decline in blood levels. The product labels specify weekly administration; the half-life is not a replacement schedule.

Must everyone reach 15 mg?

No. The maximum is not a universal target. Zepbound has several maintenance choices, and current US Mounjaro increases depend on additional blood-sugar control after the minimum time at the current dose.

Is 22.5% the head-to-head result?

No. SURMOUNT-5 reported 20.2% average loss with tirzepatide versus 13.7% with semaglutide at 72 weeks in its treatment-regimen analysis. Different trials and analyses should not be mixed.

Can a graph predict nausea or appetite?

No. The graph illustrates concentration under stated assumptions. Symptoms and treatment response need to be assessed separately.

Sources

Current labels and original studies

Checked October 12, 2026. Dose examples use US adult injection labels; brand indications differ in other countries.